TY - JOUR
T1 - Chronic haloperidol and chlorpromazine treatment alters in vitro β-endorphin metabolism in rat brain
AU - Konings, Pierre N.M.
AU - Culling-Berglund, Alison
AU - Davis, Thomas P.
PY - 1990/11/27
Y1 - 1990/11/27
N2 - To determine if chronic haloperidol (3.0 mg/kg per day) or chlorpromazine (4.2 mg/kg per day) treatment alters central β-endorphin metabolism, haloperidol and chlorpromazine were perfused via AlzetTM minipumps into male Sprague-Dawley rats for 8 days. Crude twice-washed membranes, purified synaptic plasma membranes and Golgi-enriched membranes, respectively, were isolated from rat brains and time course incubated with β-endorphin. All samples were analyzed by high resolution, reversed-phase high performance liquid chromatography. The half-lives of β-endorphin for animals treated with haloperidol or chlorpromazine were not statistically different from control animals at the crude washed membranes. At the purified synaptic plasma membranes, however, the half-lives of β-endorphin from haloperidol (t 1 2 = 45.1 min)- and chlorpromazine (t 1 2 = 47.0 min)-treated animals were significantly decreased as compared to the control animals (t 1 2 = 78.0 min). The half-life of β-endorphin at the Golgi-enriched membranes was increased for haloperidol (t 1 2 = 112.3 min) and chlorpromazine (t 1 2 = 103.0 min)-treated animals when compared to control animals (t 1 2 = 80.2 min). The findings indicate a differential effect of the dopamine receptor antagonists haloperidol and chlorpromazine on the extracellular fate at the synaptic plasma membranes of β-endorphin and the intracellular processing at the Golgi-enriched membranes in vitro.
AB - To determine if chronic haloperidol (3.0 mg/kg per day) or chlorpromazine (4.2 mg/kg per day) treatment alters central β-endorphin metabolism, haloperidol and chlorpromazine were perfused via AlzetTM minipumps into male Sprague-Dawley rats for 8 days. Crude twice-washed membranes, purified synaptic plasma membranes and Golgi-enriched membranes, respectively, were isolated from rat brains and time course incubated with β-endorphin. All samples were analyzed by high resolution, reversed-phase high performance liquid chromatography. The half-lives of β-endorphin for animals treated with haloperidol or chlorpromazine were not statistically different from control animals at the crude washed membranes. At the purified synaptic plasma membranes, however, the half-lives of β-endorphin from haloperidol (t 1 2 = 45.1 min)- and chlorpromazine (t 1 2 = 47.0 min)-treated animals were significantly decreased as compared to the control animals (t 1 2 = 78.0 min). The half-life of β-endorphin at the Golgi-enriched membranes was increased for haloperidol (t 1 2 = 112.3 min) and chlorpromazine (t 1 2 = 103.0 min)-treated animals when compared to control animals (t 1 2 = 80.2 min). The findings indicate a differential effect of the dopamine receptor antagonists haloperidol and chlorpromazine on the extracellular fate at the synaptic plasma membranes of β-endorphin and the intracellular processing at the Golgi-enriched membranes in vitro.
KW - (HPLC)
KW - Brain
KW - Neuroleptic drugs
KW - β-Endorphin
KW - β-Endorphin metabolism
UR - http://www.scopus.com/inward/record.url?scp=0025644293&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025644293&partnerID=8YFLogxK
U2 - 10.1016/0014-2999(90)94139-O
DO - 10.1016/0014-2999(90)94139-O
M3 - Article
C2 - 2086234
AN - SCOPUS:0025644293
SN - 0014-2999
VL - 191
SP - 115
EP - 128
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 2
ER -